Feminist Review 72 (1):40-52 (2002)

Within the world of pharmacology, the male body has traditionally been taken as the biological norm. Coupled with this, concern about danger to the unborn foetus has meant that, until very recently, ‘women of childbearing potential’ were routinely excluded from most of the early phases of clinical drug testing. Consequently, most drugs tested during Phase I trials were initially carried out on healthy male volunteers. During subsequent phases when drugs were tested on patients, women remained largely under-represented. As a result, some drugs prescribed for women have later been discovered to be lacking in efficacy, and women are more likely to suffer adverse drug reactions than men. The exclusion of women during the early phases of clinical drug trials has now been lifted and drugs are currently being more widely tested on women. This paper examines the differing political and ethical positions adopted by the pharmaceutical industry, drug regulators, pharmacologists, women's groups and patient activists in relation to the exclusion and inclusion of women in clinical drug trials.
Keywords No keywords specified (fix it)
Categories No categories specified
(categorize this paper)
DOI 10.1057/palgrave.fr.9400055
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 71,436
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

Principles of Biomedical Ethics.Tom L. Beauchamp - 1979 - Oxford University Press.
Case Studies in Medical Ethics.Robert M. Veatch - 1977 - Harvard University Press.

Add more references

Citations of this work BETA

Add more citations

Similar books and articles

Institutional Mistrust in the Organization of Pharmaceutical Clinical Trials.Jill A. Fisher - 2008 - Medicine, Health Care and Philosophy 11 (4):403-413.
Five Un‐Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.
Pharmacogenetics: The Bioethical Problem of DNA Investment Banking.Oonagh P. Corrigan & Bryn Williams-Jones - 2006 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 37 (3):550-565.
Empty Ethics: The Problem with Informed Consent.Oonagh Corrigan - 2003 - Sociology of Health & Illness 25 (3):768-792.
Bioethics, Vulnerability, and Protection.Ruth Macklin - 2003 - Bioethics 17 (5-6):472--486.


Added to PP index

Total views
1 ( #1,552,974 of 2,520,355 )

Recent downloads (6 months)
1 ( #406,012 of 2,520,355 )

How can I increase my downloads?


Sorry, there are not enough data points to plot this chart.

My notes